

DDI-fficult Decisions: Navigating Drug Interactions in Oral Oncology Regimens

February 12, 2026 | 1200-1300 CST/1300-1400 EST
VC-WI St Lukes Family Practice LL and Virtual via Teams Webinar

Overview: This continuing education course will cover the clinically significant drug–drug interactions (DDIs) associated with oral anticancer therapies. The presentation will cover potential adverse effects of DDIs and examine key interaction pathways, including those involving CYP3A4 inhibitors and inducers, gastric acid–suppressing agents, and medications that prolong the QT interval. Strategies for identifying, preventing, and managing these interactions will be discussed to help ensure patient safety and maintain optimal therapeutic efficacy.

Speaker: Sandi Thein Sein, PharmD, PGY2 Oncology Pharmacy Resident – Aurora St. Luke's Medical Center

Preceptors: Cara Boticki, PharmD, BCOP; Laura Poggi, PharmD, BCOP

Objectives:

1. Identify oral oncology agents with high drug–drug interaction (DDI) risk and describe the key pharmacokinetic and pharmacodynamic mechanisms that contribute to potential interaction.
2. Explain how drug interactions involving CYP3A4 inhibitors and inducers influence clinical outcomes.
3. Describe the ways acid-suppressing agents interact with oral chemotherapy therapies and summarize considerations for management.
4. Explain how QT-prolonging agents interact with oral chemotherapy and outline key principles to monitor and prevent QTc prolongation.

Target Audience: Advocate Health Pharmacists, Physicians, Nurses, and other interested healthcare professionals

Disclosure: Alex Wolff, Bristol Myers Squibb, Advisory Board, ended 9/25/25; Syndax Pharmaceuticals, Advisory Board, ended 4/8/25; the other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.

Link to Live Sessions: [Pharmacy Grand Rounds 2026](#)

Commercial Support: There is no financial support for this activity.

Accreditation Statement:



In support of improving patient care, Advocate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Statement(s):

Accreditation Council for Pharmacy Education (ACPE):

Advocate Health designates this live activity for a maximum of 1 hour of CPE credit for pharmacists. CPE credit can be claimed on the AH CE platform within 60 days of activity completion and information will be provided to CPE Monitor. Participants should only claim credit commensurate with the extent of their participation in the activity.
UAN: JA0006327-0000-26-001-L01-P

American Medical Association (AMA): Advocate Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC): Advocate Health designates this live activity for a maximum of 1.0 ANCC contact hours/APRN pharmacological hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Contact Elaine Thomas (elaine.r.thomas@advocatehealth.org) with questions.

